Rules Update – February 2017

The following rule changes will take effect in February 2017:

4729-5-02 (Rescind) - Removes the requirement that a pharmacist and intern must sign their identification card. **Effective 2/1/2017**

4729-5-03 (Rescind) - Rescinds rule requiring a demographic questionnaire upon renewal. The text of this rule is being incorporated into amended 4729-7-02. **Effective 2/1/2017**

4729-5-07 (Amend) - Recognizes and approves schools of pharmacy as required by section 4729.08 of the Ohio Revised Code. **Effective 2/1/2017**

4729-7-02 (Amend) - Requires the completion of a demographic questionnaire upon renewal of a pharmacist or pharmacy intern license. **Effective 2/1/2017**

4729-9-04 (Amend) - Unless under specific circumstances, prohibits a drug that has been dispensed pursuant to a prescription or personally furnished by a prescriber and has left the physical premises of the terminal distributor of dangerous drugs from being dispensed or personally furnished again. **Effective 2/1/2017**

4729-9-16 (Amend) - Specifies the minimum standards for wholesalers. The rule is being amended to specify the required information on an application as well as the individuals who are subject to a background check. **Effective 2/15/2017**

4729-9-28 (Amend) - Specifies the minimum standards for virtual wholesalers. The rule is being amended to specify the required information on an application as well as the individuals who are subject to a background check. **Effective 2/15/2017**

4729-9-29 (Amend) - Specifies the minimum standards for third party logistics providers. The rule is being amended to specify the required information on an application as well as the individuals who are subject to a background check. **Effective 2/15/2017**

*A copy of the amended rules is included in this document.*
Recognized and approved schools of pharmacy.

(A) To be recognized and approved by the state board of pharmacy, a school of pharmacy shall meet the requirements as set forth by the board. The board may utilize the reports, requirements, and recommendations of any recognized accrediting organization or higher education governing board in determining the requirements. The board of pharmacy shall take into consideration, but not be bound by, accreditation standards established by the "Accreditation Council for Pharmacy Education."

(A) Pursuant to section 4729.08 of the Ohio Revised Code, the state board of pharmacy recognizes and approves all pharmacy programs or schools of pharmacy that have candidate or accreditation status with Accreditation Council for Pharmacy Education (A.C.P.E.). The Board, by resolution, reserves the right to:

1) Deny the recognition or approval of a pharmacy program or school of pharmacy that meets A.C.P.E. candidate or accreditation status; or

2) Recognize or approve a pharmacy program or school of pharmacy that does not meet A.C.P.E. candidate or accreditation status.

(B) For the purpose of satisfying the requirements of division (C) of section 4729.08 of the Revised Code, graduates of a school of pharmacy located outside the United States shall establish educational equivalency by obtaining a "Foreign Pharmacy Graduate Examination Commission (FPGEC)" certificate, and by establishing proficiency in spoken English by obtaining the minimum scores required by rule 4729-5-34 of the Administrative Code on the or the "Test of English as a Foreign Language, Internet-based test (TOEFL iBT)."

(C) The term "United States," as used in paragraph (B) of this rule, shall be deemed to include all states of the United States, the District of Columbia, and all territories and any commonwealths.
4729-7-02  

Requirements for renewal of a pharmacist identification card.

(A) Except as provided in rule 4729-7-08 of the Administrative Code, evidence of six C.E.U.s of approved continuing education shall be submitted to the board no later than September fifteenth of the year in which evidence of the continuing pharmacy education is required for identification card renewal. At least 0.3 C.E.U.s of the total required C.E.U.s must be obtained in pharmacy jurisprudence and at least 0.2 C.E.U.s of the total required C.E.U.s must be obtained in patient or medication safety.

(B) The C.E.U.s must be obtained within a period of time that is no more than three years prior to September fifteenth of the year in which evidence of the continuing pharmacy education is required for identification card renewal. If reporting continuing education is required after a pharmacist's license has lapsed or where the license is being renewed after board action, continuing education must be obtained during the three year period immediately preceding the date the renewal application is filed with the board office.

(C) C.E.U.s obtained in excess of the required C.E.U.s at the time the continuing education is required for identification card renewal, may not be transferred and applied to future requirements.

(D) For the first four C.E.U. reporting years following the adoption of this rule (2014, 2015, 2016 and 2017), the board may accept C.E.U.s within a period of time from March first, three years prior to September fifteenth of the year in which evidence of the continuing pharmacy education is required for identification card renewal.

(E) A pharmacist whose identification card has lapsed or has been suspended may renew his/her identification card, if he/she qualifies for renewal pursuant to section 4729.12 or section 4729.13 of the Revised Code, by paying the required fee, completing the application for renewal, and, if he/she would have been required to report continuing pharmacy education during the period of lapse or suspension, by providing evidence of having obtained the number of C.E.U.s required at the time of renewal by submitting the certificates of participation obtained during the three-year period immediately preceding the date of applying for renewal.

(F) Ohio-registered pharmacists who hold a current license in states where continuing education is mandatory, have met the continuing pharmacy education requirements of that state, and who do not practice pharmacy in Ohio, may renew their identification card by paying the required fee, completing the application for renewal, and submitting the following signed statement on their continuing pharmacy education report form:
"I declare under penalties of falsification that I hold a current and valid pharmacist license, number (insert license number), in the state of (insert name of state), that I have met the continuing pharmacy education requirements of this state and I do not presently practice pharmacy in the state of Ohio. I hereby agree to immediately notify the Ohio state board of pharmacy if I return and commence the practice of pharmacy in the state of Ohio."

(G) The state board of pharmacy may grant extension periods and waivers for the completion of license renewal and continuing education requirements for active military service members and their spouses. If a current pharmacist or their spouse is called to active duty for military service, the time period allowed for completion of any continuing education requirements will be extended by the amount of time that the pharmacist or the pharmacist’s spouse was on active duty. A pharmacist seeking an extension period or waiver must provide documentation to the board demonstrating active-duty service.

(H) If a pharmacist is a member of the armed forces, reserves, the Ohio national guard, the Ohio military reserve, or the Ohio naval militia, the state board of pharmacy shall consider relevant military education, training or service that has been completed by the license holder when determining the fulfillment of any continuing education requirements.

(I) An applicant for renewal of a pharmacist or pharmacy intern license shall complete the questionnaire which is part of the application provided for this purpose. Questions for the annual inventory data shall be limited to professional demographic information.
4729-9-04 Returned drugs.

(A) No drug that has been dispensed pursuant to a prescription or personally furnished by a prescriber and has left the physical premises of the terminal distributor of dangerous drugs shall be dispensed or personally furnished again except:

(1) Drugs dispensed for inpatients pursuant to paragraph (C) of rule 4729-17-01 of the Administrative Code or personally furnished to inpatients provided that:

(a) The drugs are packaged in unopened, single-dose or tamper-evident containers and

(b) The drugs have not been in the possession of the ultimate user.

(2) Non-controlled drugs dispensed by a government entity and delivered for outpatients to a psychiatric outpatient facility or to any service provider licensed with the state board of pharmacy provided that:

(a) The drugs are packaged in unopened, single-dose or tamper-evident containers and

(b) The drugs have not been in the possession of the ultimate user.

(B) Drugs that have not been dispensed, personally furnished or possessed in accordance with this rule are considered to be adulterated.
Minimum requirements for wholesalers.

The following minimum requirements shall apply to all persons distributing dangerous drugs at wholesale in Ohio:

(A) The following information shall be required on a form supplied by the state board of pharmacy from each person making application for a license as a wholesale distributor of dangerous drugs:

(1) The name, full physical business address (not a post office box), and telephone number. 

(2) All trade, fictitious, or business names used by the licensee (e.g. "doing business as" or "formerly known as"). Trade or business names shall not be identical to the name used by another, unrelated wholesale distributor permitted to purchase drugs in the state. 

(2) All trade or business names used by the licensee, any trade or business names under which licensee was previously or is presently licensed.

(3) Addresses, telephone numbers, and the full names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of dangerous drugs.

(4) The type of ownership or operation (i.e., sole proprietorship, partnership, corporation, or government agency). 

(5) The following information for the owner(s) and/or operator(s) of the wholesale distributor:

(a) For a partnership:

(i) the full name, business address, Social Security number, and date of birth of each partner; if the partner is not a natural person each business entity that is a partner having an ownership interest must be disclosed on the application up to and through the entity that is owned by a natural person; 

(ii) the name of the partnership; and

(iii) the partnership's federal employer identification number.

(b) For a corporation:

(i) the full name, business address, Social Security number and date of birth of the corporation's president, vice-president, secretary,
treasurer and chief executive officer, or any equivalent position:

(ii) the name or names of the corporation;

(iii) the state of incorporation;

(iv) the corporation's federal employer identification number;

(v) the name of the parent company, if applicable;

(vi) if the corporation is not publicly traded on a major stock exchange, the full name, business address, and social security number of each shareholder owning ten percent or more of the voting stock of the corporation.

(c) For a sole proprietorship:

(i) the full name, business address, Social Security number, and date of birth of the sole proprietor; and

(ii) if applicable, the federal employer identification number of the business entity.

(d) For a government agency: the full name, business address, Social Security number, and date of birth of the agency director.

(5) The full name(s) of the owner and/or operator of the licensee, including:

(a) If a sole proprietorship, the full name of the sole proprietor, and the name of the business entity;

(b) If a partnership, the full name of each partner, and the name of the partnership;

(c) If a corporation, the full name and title of each corporate officer and director, the corporate names, the name of the state of incorporation, the corporation number, and a copy of the corporation papers;

(d) If a government agency, the name of the agency, and the full name of each officer and director of the agency.

(6) If the entity making application for a wholesale distributor of dangerous drugs license is located outside the boundaries of the state of Ohio, part of the licensing process shall be an inquiry to the licensing authority of the state or jurisdiction in which that entity is located. This inquiry will determine whether the entity possesses a current and valid license to distribute dangerous drugs in that state or jurisdiction and the experience the licensing
authority has had with the entity. This information will be used as part of the consideration in licensing the entity by the Ohio state board of pharmacy. The Ohio board will respond to inquiries of a similar nature from other states about licensees in Ohio.

(7) Pursuant to section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license will not be issued until the following submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check:

(a) The responsible person on the application for licensure of a wholesale distributor pursuant to 4729-5-11; and

(b) The following persons based upon the wholesale distributor's business type:

(i) All partners of a partnership;

(ii) The sole proprietor of a sole proprietorship;

(iii) The president, vice president, secretary, treasurer, and chief executive officer, or any equivalent position of a corporation and, if a corporation is not publicly traded on a major stock exchange, each shareholder owning ten percent or more of the voting stock of the corporation;

(iv) The agency director of a government agency.

(c) The persons listed in paragraph (A)(7)(b) shall be a natural person that owns and/or operates the business entity applying for licensure. In the event the applicant is not owned by a natural person, each business entity with an ownership interest in the applicant must be disclosed on the application up to and through the entity that is owned by a natural person, who shall be subject to a background check in accordance with this rule.

(8) If there is a change in any of the following persons listed in paragraph (A)(7) of this rule, the new persons shall submit to a criminal records check within thirty days of the change.

(9) All criminal records checks conducted in accordance with this rule shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of the required criminal
records checks the licensing process will proceed. The persons listed in paragraph (A)(7) of this rule may submit electronic fingerprint impressions as described to rule 4729-5-12 of the Administrative Code, or, if located outside of Ohio, they may submit fingerprint impressions in a manner approved by the board.

(10) Any information required on the application as determined by the board.

(11) Any follow-up information as deemed necessary upon receipt of the application materials.

(7) Pursuant to division (A)(1) of section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license will not be issued until the owner(s), the officers (if incorporated) or agency directors (if a government agency) of the wholesale operation submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check. If there is a change in officers, owners or agency directors, all new officers, owners or agency directors shall submit to a criminal records check. The criminal records check shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the Ohio state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of the required criminal records checks the license process will proceed. The owner(s) or officers may submit electronic fingerprint impressions pursuant to rule 4729-5-12 of the Administrative Code, or if located outside of Ohio they may submit ink fingerprint impressions as instructed on a form provided by the board.

(B) Prior to the end of the licensing period, a renewal application requesting such information as the state board of pharmacy may require will be sent to the address of record to the attention of the responsible person. Such renewal application form shall be completed and returned with the applicable fee on or before the established deadline.

(C) All facilities where dangerous drugs are stored, warehoused, handled, held, offered, marketed, or displayed shall:

(1) Be of suitable size and construction to facilitate cleaning, maintenance, and proper operations;

(2) Have storage areas designed to provide adequate lighting, ventilation, temperature, sanitation, humidity, space, equipment, and security conditions;
(3) Have a quarantine area for storage of dangerous drugs that are outdated, damaged, deteriorated, misbranded, or adulterated, or that are in immediate or sealed secondary containers that have been opened. Such drugs shall be stored no longer than two years pursuant to rule 4729-9-17 of the Administrative Code;

(4) Be maintained in a clean and orderly condition;

(5) Be free from infestation by insects, rodents, birds, or vermin of any kind.

(D) All facilities used for wholesale drug distribution shall be secure from unauthorized entry.

(1) Access from outside the premises shall be kept to a minimum and be well controlled.

(2) The outside perimeter of the premises shall be well lighted.

(3) Entry into areas where dangerous drugs are held shall be limited to authorized personnel.

(4) All facilities where dangerous drugs are held shall be equipped with a state board of pharmacy approved alarm system to detect unauthorized entry after hours.

(5) All facilities shall be equipped with a security system that will provide suitable protection against theft and diversion. When appropriate, the security system shall provide protection against theft or diversion that is facilitated or hidden by tampering with computers or electronic records.

(E) All dangerous drugs shall be stored at appropriate temperatures and under appropriate conditions in accordance with requirements, if any, in the labeling of such drugs, or with requirements in the current edition of an official compendium, such as the United States pharmacopoeia/national formulary (USP/NF).

(1) If no storage requirements are established for a prescription drug, the drug may be held at "controlled" room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.
(2) Appropriate manual, electromechanical, or electronic temperature and humidity recording equipment, devices, and/or logs shall be utilized to document proper storage of dangerous drugs.

(3) The recordkeeping requirements in paragraph (H) of this rule shall be followed for all stored drugs.

(F) All shipments of dangerous drugs shall be examined in accordance with the following:

(1) Upon receipt, each outside shipping container shall be visually examined for identity and to prevent the acceptance of contaminated dangerous drugs or dangerous drugs that are otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents;

(2) Each outgoing shipment shall be carefully inspected for identity of the dangerous drug products and to ensure that there is no delivery of dangerous drugs that have been damaged in storage or held under improper conditions;

(3) The recordkeeping requirements in paragraph (H) of this rule shall be followed for all incoming and outgoing dangerous drugs.

(G) All returned, damaged, and outdated, dangerous drugs shall be handled in the following manner:

(1) Dangerous drugs that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other dangerous drugs until they are destroyed or returned to their supplier.

(2) Any dangerous drugs whose immediate or sealed outer or sealed secondary containers have been opened or used shall be identified as such, and shall be quarantined and physically separated from other dangerous drugs until they are either destroyed or returned to the supplier.

(3) If the conditions under which a dangerous drug has been returned cast doubt on the drug's safety, identify, strength, quality, or purity, then the drug shall be destroyed, or returned to the supplier, unless examination, testing, or other investigation proves that the drug meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether the conditions under which a drug has been returned cast doubt on the drug's safety, identity,
strength, quality, or purity, the wholesale drug distributor shall consider, among other things, the conditions under which the drug has been held, stored, or shipped before or during its return and the condition of the drug and its container, carton, or labeling, as a result of storage or shipping.

(4) The recordkeeping requirements in paragraph (H) of this rule shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated dangerous drugs.

(H) Wholesale drug distributors shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of dangerous drugs.

(1) These records shall include, but shall not be limited to, the following information:

(a) The source of the drugs, including the name and principle address of the seller or transferor, and the address of the location from which the drugs were shipped.

(b) The identity and quantity of the drugs received, and distributed, or disposed of or returned.

(c) The dates of receipt and distribution of the drugs.

(d) A system of records and procedures shall be maintained which prevent the sale or other distribution of dangerous drugs to any person not authorized by division (B) of in accordance with section 4729.51 of the Revised Code.

(e) A system of procedures shall be designed and operated to disclose orders for controlled substances and other dangerous drugs subject to abuse.

(i) The wholesaler shall inform the state board of pharmacy of suspicious orders for drugs, as described in paragraph (H)(1)(e) of this rule, when discovered. Suspicious orders are those which, in relation to the wholesaler's records as a whole, are of unusual size, unusual frequency, or deviate substantially from established buying patterns.

(ii) Reports, generated by the system as described in paragraph (H)(1)(e) of this rule, shall be furnished to the state board of
pharmacy within three working days of receipt of a request from the board. The reports shall include the name and address of the purchaser, date of purchases, product trade name, national drug code (NDC) number, size of package, and quantity purchased.

(2) Inventories and records shall be made available for inspection and photocopying by properly identified and authorized state board of pharmacy designated agents, and federal, state, or local law enforcement agency officials for a period of three years following disposition of the drugs.

(3) Records described in this rule that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period.

(a) Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by properly identified and authorized state board of pharmacy designated agents, and federal, state, or local law enforcement agency officials.

(b) Wholesalers intending to maintain records, described in this rule, at a location other than the place licensed by the state board of pharmacy must first send notification to the board.

(I) Wholesale drug distributors shall establish, maintain, and adhere to written policies and procedures which shall be followed for the receipt, security, storage, inventory, and distribution of dangerous drugs, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. Wholesale drug distributors shall include in their written policies and procedures the following:

(1) A procedure whereby the oldest approved stock of a dangerous drug product is distributed first. The procedure may permit deviation from this requirement, if such deviation is temporary and appropriate.

(2) A procedure to be followed for handling recalls and withdrawals of dangerous drugs. Such procedure shall be adequate to deal with recalls and withdrawals due to:

(a) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the state board of pharmacy;
(b) Any voluntary action by the manufacturer to remove defective or potentially defective drugs from the market;

(c) Any action undertaken to promote public health and safety by replacing of existing merchandise with an improved product or new package design.

(3) A procedure to ensure that wholesale drug distributors prepare for, protect against, and handle any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency.

(4) A procedure to ensure that any outdated dangerous drugs shall be segregated from other drugs and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of outdated dangerous drugs. This documentation shall be maintained for three years after disposition of the outdated drugs.

(J) Wholesale distributors of dangerous drugs shall establish and maintain accurate and current lists of officers, directors, managers, and other persons in charge of wholesale drug distribution, storage, and handling, including a description of their duties and a summary of their qualifications. A wholesale distributor of dangerous drugs shall have a responsible person pursuant to rule 4729-5-11 of the Administrative Code.

(K) Personnel employed in the wholesale distribution of dangerous drugs shall be required to have appropriate education and/or experience to assume responsibility for positions related to compliance with the licensing regulations.

(L) Wholesale drug distributors shall operate in compliance with applicable federal, state, and local laws and regulations.

(1) Wholesale drug distributors shall permit properly identified and authorized state board of pharmacy designated agents, and federal, state, and local law enforcement officials to enter and inspect their premises and delivery vehicles, and to audit their records and written operating procedures at reasonable times and in a reasonable manner, to the extent authorized by law.

(2) Any entity making a wholesale sale of a controlled substance shall be required to possess a license as a wholesale distributor of dangerous drugs and a license as a wholesaler or manufacturer of controlled substances, except that a licensed terminal distributor of dangerous drugs may make an occasional sale of a controlled substance pursuant to rule 4729-9-10 of the Administrative
(M) Wholesale drug distributors shall be subject to the provisions of any applicable federal, state, or local laws or regulations that relate to dangerous drug salvaging or reprocessing.

(N) The state board of pharmacy shall be notified of any new facilities, work or storage areas to be constructed or utilized for dangerous drugs or of any changes in operation of the registrant wholesale distributor being used or implemented.
Licensure as a virtual wholesale distributor/broker.

(A) "Virtual Wholesale Distributor/Broker" means any person engaged in wholesale distribution of dangerous drugs in or into Ohio which:

(1) Has title but does not take physical possession of dangerous drugs;

(2) Shall be licensed by the state board of pharmacy as a wholesale distributor pursuant to section 4729.52 of the Revised Code with a virtual wholesale distributor/broker classification; and

(3) Shall be registered as a business entity with the appropriate state or local authority(s) and must operate out of a location that is zoned for commercial use and not out of a residence or personal dwelling.

(B) The following information shall be required on a form supplied by the state board of pharmacy from each person making application for a license as a wholesale distributor of dangerous drugs with a virtual wholesale distributor/broker classification:

(1) The name, full physical business address (not a post office box), and telephone number;

(2) All trade or business names used by the licensee, any trade or business names under which licensee was previously or is presently licensed. All trade, fictitious, or business names used by the licensee, e.g. "doing business as" or "formerly known as". Trade or business names shall not be identical to the name used by another, unrelated wholesale distributor permitted to purchase drugs in the state.

(3) Addresses, telephone numbers, and the full names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of dangerous drugs;

(4) The type of ownership or operation (i.e., sole proprietorship, partnership, corporation, or government agency);

(5) The following information for the owner(s) and/or operator(s) of the wholesale distributor with a virtual wholesale distributor classification:

(a) For a partnership:

(i) the full name, business address, Social Security number, and date of birth of each partner; if the partner is not a natural person each
business entity that is a partner having an ownership interest must be disclosed on the application up to and through the entity that is owned by a natural person;

(ii) the name of the partnership; and

(iii) the partnership's federal employer identification number.

(b) For a corporation:

(i) the full name, business address, Social Security number and date of birth of the corporation's president, vice-president, secretary, treasurer and chief executive officer, or any equivalent position;

(ii) the name or names of the corporation;

(iii) the state of incorporation;

(iv) the corporation's federal employer identification number;

(v) the name of the parent company, if applicable; and

(vi) if a corporation is not publicly traded on a major stock exchange, the full name, business address, and Social Security number of each shareholder owning ten percent or more of the voting stock of the corporation.

(c) For a sole proprietorship:

(i) the full name, business address, Social Security number, and date of birth of the sole proprietor; and

(ii) if applicable, the federal employer identification number of the business entity.

(d) For a government agency: the full name, business address, Social Security number, and date of birth of the agency director.

(5) The full name(s) of the owner and/or operator of the licensee, including:

(a) If a sole proprietorship, the full name of the sole proprietor, and the name of the business entity;

(b) If a partnership, the full name of each partner, and the name of the partnership;

(e) If a corporation, the full name and title of each corporate officer and
director, the corporate names, the name of the state of incorporation, the corporation number, and a copy of the corporation papers;

(d) If a government agency, the name of the agency, and the full name of each officer and director of the agency.

(6) A copy of any existing licensure the entity has from the state or jurisdiction in which it is located or a letter from a state licensing entity authority in that state or jurisdiction where the virtual wholesaler is located that indicates that the state or jurisdiction does not license such entities.

(7) A copy of any applicable federal licensure or registration, including a drug enforcement agency registration if distributing controlled substances.

(8) If the entity making application for a wholesale distributor of dangerous drugs license with a virtual wholesale distributor/broker classification is located outside the boundaries of the state of Ohio, part of the licensing process shall be an inquiry to the licensing authority of the state or jurisdiction in which that entity is located. This inquiry will determine whether the entity possesses a current and valid license to distribute dangerous drugs in that state or jurisdiction and the experience the licensing authority has had with the entity. This information will be used as part of the consideration in licensing the entity by the board of pharmacy. The board will respond to inquiries of a similar nature from other state or jurisdictional licensing authorities regarding Ohio licensed entities. If a state or jurisdiction does not license virtual wholesale distributors/brokers as defined in paragraph (A) of this rule, the facility must maintain verified-accredited wholesale distributors (VAWD) accreditation from the national association of boards of pharmacy.

(9) Pursuant to section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license with a virtual wholesale distributor/broker classification will not be issued until the following submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check:

(a) The responsible person on the application for licensure of a wholesale distributor pursuant to 4729-5-11; and

(b) The following persons based upon the wholesale distributors business type:

(i) All partners of a partnership;

(ii) The sole proprietor of a sole proprietorship;
(iii) The president, vice president, secretary, treasurer, and chief executive officer, or any equivalent position of a corporation and if a corporation is not publicly traded on a major stock exchange, each shareholder owning ten percent or more of the voting stock of the corporation;

(iv) The agency director of a government agency.

(c) The persons listed in paragraph (B)(9)(b) of this rule shall be a natural person that owns and/or operates the business entity applying for licensure. In the event the applicant is not owned by a natural person, each business entity with an ownership interest in the applicant must be disclosed on the application up to and through the entity that is owned by a natural person, who shall be subject to a background check in accordance with this rule.

(10) If there is a change in any of the following persons listed in paragraph (B)(9) of this rule, the new persons shall submit to a criminal records check within thirty days of the change.

(9) Pursuant to division (A)(1) of section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license with a virtual wholesale distributor/broker classification will not be issued until the owner(s), the officers (if incorporated) or agency directors (if a government agency) of the wholesale operation submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check. If there is a change in officers, owners or agency directors, all new officers, owners or agency directors shall submit to a criminal records check. The criminal records check shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the Ohio state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of the required criminal records checks the license process will proceed. The owner(s) or officers may submit electronic fingerprint impressions pursuant to rule 4729-5-12 of the Administrative Code, or, if located outside of Ohio, they may submit ink fingerprint impressions as instructed on a form provided by the board.

(11) All criminal records checks conducted in accordance with this rule shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of
the required criminal records checks the licensing process will proceed. The persons listed in paragraph (B)(9) of this rule may submit electronic fingerprint impressions as described in rule 4729-5-12 of the Administrative Code, or, if located outside of Ohio, the person may submit fingerprint impressions in a manner approved by the board.

(12) Any additional information required on the application as determined by the board.

(13) Any follow-up information as deemed necessary upon receipt of the application materials.

(10) Any additional information as the state board of pharmacy may require.

(C) Prior to the end of the licensing period, a renewal application requesting such information as the state board of pharmacy may require will be sent to the attention of the responsible person. Such a renewal application shall be completed and returned with the applicable fee on or before the established deadline. As part of the renewal application, a person meeting the definition of a virtual wholesaler/broker that was licensed by the board as a wholesale distributor of dangerous drugs prior to the effective date of this rule shall demonstrate compliance with the requirements in paragraph (B)(8) of this rule. Failure to do so may result in a refusal by the board to renew the license.

(D) Virtual wholesale distributors/brokers shall establish and maintain inventories and records of all transactions regarding the receipt and distribution or other disposition of dangerous drugs.

(1) These records shall include, but shall not be limited to, the following information:

(a) The source of the drugs, including the all of the following:

(i) Name and principle address of the seller or transferor;

(ii) The address of the location from which the drugs were shipped; and

(iii) Verification that the seller or transferor is appropriately licensed to sell or transfer dangerous drugs at wholesale.

(b) The identity and quantity of the drugs received, and distributed, or disposed or returned, of.
(c) The dates of receipt and distribution of the drugs.

(d) A system of records and procedures shall be maintained which prevent the sale or other distribution of dangerous drugs to any person not authorized by division (B) of in accordance with section 4729.51 of the Revised Code.

(e) A system shall be designed and operated to disclose orders for controlled substances and other dangerous drugs subject to abuse. Reports generated by the system shall be furnished to the state board of pharmacy within three working days of receipt of a request from the board. The reports shall include the name and address of the purchaser, date of purchases, product trade name, national drug code (NDC) number, size of package, and quantity purchased.

(2) Inventories and records shall be made available for inspection and photocopying by properly identified and authorized state board of pharmacy designated agents and federal, state, or local law enforcement agency officials for a period of three years following disposition of the drugs.

(3) Records described in this rule that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period.

(a) Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by properly identified and authorized state board of pharmacy designated agents and federal, state, or local law enforcement agency officials.

(b) Virtual wholesale distributors/brokers intending to maintain records described in this rule, at a location other than the place licensed by the state board of pharmacy, must obtain approval from the board.

(E) The virtual wholesale distributors/broker shall inform the state board of pharmacy of suspicious orders for controlled substances and other dangerous drugs subject to abuse, immediately upon discovery. Suspicious orders are those which, in relation to the wholesaler's records as a whole, are of unusual size, unusual frequency, or deviate substantially from established buying patterns.

(F) Virtual wholesale distributors/brokers shall establish, maintain, and adhere to written policies and procedures which shall be followed for the receipt, security, storage,
inventory, and distribution of dangerous drugs, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. At a minimum, virtual wholesale distributors/brokers shall include in their written policies and procedures the following:

(1) A procedure whereby the oldest approved stock of a dangerous drug product is distributed first. The procedure may permit deviation from this requirement, if such deviation is temporary and appropriate.

(2) A procedure to be followed for handling recalls and withdrawals of dangerous drugs. Such procedure shall address recalls and withdrawals due to:

   (a) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the state board of pharmacy;

   (b) Any voluntary action by the manufacturer to remove defective or potentially defective drugs from the market;

   (c) Any action undertaken to promote public health and safety by replacing of existing merchandise with an improved product or new package design.

(3) A procedure to ensure that virtual wholesale distributors/brokers prepare for, protect against, and handle any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency.

(4) A procedure to ensure that any adulterated dangerous drugs shall be segregated from other drugs and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of outdated dangerous drugs. This documentation shall be maintained for three years after disposition of the outdated drugs.

(5) This documentation shall be maintained for three years after disposition of the outdated drugs.

(G) Wholesale distributors of dangerous drugs shall establish and maintain accurate and current lists of officers, directors, managers, and other persons in charge of wholesale drug distribution, storage, and handling, including a description of their duties and a summary of their qualifications.
(H) Personnel employed in the wholesale distribution of dangerous drugs shall be required to have appropriate education and/or experience to assume responsibility for positions related to compliance with the licensing regulations.

(I) Virtual wholesale drug distributors shall operate in compliance with applicable federal, state, and local laws and regulations.

(1) Virtual wholesale distributors shall permit properly identified and authorized state board of pharmacy designated agents and federal, state, and local law enforcement officials to enter and inspect their premises and delivery vehicles, and to audit their records and written operating procedures at reasonable times and in a reasonable manner, to the extent authorized by law.

(2) Any virtual wholesale distributor making a wholesale sale of a controlled substance shall be required to possess a license as a wholesale distributor of dangerous drugs with a virtual wholesale distributor classification and a license as a wholesaler or manufacturer of controlled substances, except that a licensed terminal distributor of dangerous drugs may make an occasional sale of a controlled substance pursuant to rule 4729-9-10 of the Administrative Code.

(J) Virtual wholesale distributors shall be subject to the provisions of any applicable federal, state, or local laws or regulations that relate to dangerous drug salvaging or reprocessing.

(K) The state board of pharmacy shall be notified within thirty days of any new facilities, work or storage areas to be constructed or utilized for dangerous drugs or of any changes in operation of the registrant virtual wholesale distributor being used or implemented.

(L) The virtual wholesale distributors shall comply with Title II of the Drug Quality and Security Act (9/3/2015).

(M) Virtual wholesale distributors shall submit wholesale sale information to the board of pharmacy in accordance with Chapter 4729-37 of the Administrative Code.
Licensure as a third party logistics provider.

(A) "Third party logistics provider" means any person who:

(1) Contracts with a manufacturer or wholesale distributor of dangerous drugs to provide or coordinate warehousing, distribution, or other services on behalf of a manufacturer or wholesaler, but does not take title to or have general responsibility to direct the dangerous drug’s sale or disposition;

(2) Is licensed by the state board of pharmacy as a wholesale distributor pursuant to section 4729.52 of the Revised Code with a third party logistics provider classification; and

(3) Shall be registered as a business entity with the appropriate state or local authority(s) and must operate out of a location that is zoned for commercial use and not out of a residence or personal dwelling.

(B) The following information shall be required on a form supplied by the state board of pharmacy from each person making application for a license as a wholesale distributor of dangerous drugs with a third party logistics provider classification:

(1) The name, full physical business address (not a post office box), and telephone number;

(2) All trade, fictitious, or business names used by the licensee (e.g. "doing business as" or "formerly known as"). Trade or business names shall not be identical to the name used by another, unrelated wholesale distributor permitted to purchase drugs in the state;

(3) Addresses, telephone numbers, and the full names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of dangerous drugs;

(4) The type of ownership or operation (i.e., sole proprietorship, partnership, corporation, or government agency);

(5) The following information for the owner(s) and/or operator(s) of the wholesale distributor:

(a) For a partnership:
(i) the full name, business address, Social Security number, and date of birth of each partner; if the partner is not a natural person each business entity that is a partner having an ownership interest must be disclosed on the application up to and through the entity that is owned by a natural person;

(ii) the name of the partnership; and

(iii) the partnership's federal employer identification number.

(b) For a corporation:

(i) the full name, business address, Social Security number and date of birth of the corporation's president, vice-president, secretary, treasurer and chief executive officer, or any equivalent position;

(ii) the name or names of the corporation;

(iii) the state of incorporation;

(iv) the corporation's federal employer identification number;

(v) the name of the parent company, if applicable; and

(vi) if a corporation is not publicly traded on a major stock exchange, the full name, business address, and Social Security number of each shareholder owning ten percent or more of the voting stock of the corporation.

(c) For a sole proprietorship:

(i) the full name, business address, Social Security number, and date of birth of the sole proprietor; and

(ii) if applicable, the federal employer identification number of the business entity.

(d) For a government agency: the full name, business address, Social Security number, and date of birth of the agency director.

(5) The full name(s) of the owner and/or operator of the licensee, including:

(a) If a sole proprietorship, the full name of the sole proprietor, and the name of the business entity;

(b) If a partnership, the full name of each partner, and the name of the
partnership;

(c) If a corporation, the full name and title of each corporate officer and director, the corporate names, the name of the state of incorporation, the corporation number, and a copy of the corporation papers;

(d) If a government agency, the name of the agency, and the full name of each officer and director of the agency;

(6) A copy of any existing licensure the entity has from the state or jurisdiction in which it is located or a letter from a state licensing authority in that state or jurisdiction entity where it is the third party logistics provider is located that indicates that the state or jurisdiction does not license such entities;

(7) A copy of any applicable federal licensure or registration;

(8) If the entity making application for a wholesale distributor of dangerous drugs license with a third party logistics provider classification is located outside the boundaries of the state of Ohio, part of the licensing process shall be an inquiry to the licensing authority of the state or jurisdiction in which that entity is located. This inquiry will determine whether the entity possesses a current and valid license to distribute dangerous drugs in that state or jurisdiction and the experience the licensing authority has had with the entity. This information will be used as part of the consideration in licensing the entity by the board of pharmacy. The board will respond to inquiries of a similar nature from other state or jurisdictional licensing authorities regarding Ohio licensed entities. If a state does not license such entities, the facility must maintain verified-accredited wholesale distributors (VAWD) accreditation from the national association of boards of pharmacy.

(9) Pursuant to section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license will not be issued until the following submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check:

(a) The responsible person on the application for licensure of a wholesale distributor pursuant to 4729-5-11; and

(b) The following persons based upon the wholesale distributor's business type:

(i) All partners of a partnership;

(ii) The sole proprietor of a sole proprietorship;
(iii) The president, vice president, secretary, treasurer, and chief executive officer, or any equivalent position of a corporation and if a corporation is not publicly traded on a major stock exchange, each shareholder owning ten percent or more of the voting stock of the corporation;

(iv) The agency director of a government agency.

(c) The persons listed in paragraph (B)(9)(b) of this rule shall be a natural person that owns and/or operates the business entity applying for licensure. In the event the applicant is not owned by a natural person, each business entity with an ownership interest in the applicant must be disclosed on the application up to and through the entity that is owned by a natural person, who shall be subject to a background check in accordance with this rule.

(10) All criminal records checks conducted in accordance with this rule shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of the required criminal records checks the licensing process will proceed. The persons listed in paragraph (B)(9) of this rule may submit electronic fingerprint impressions pursuant to rule 4729-5-12 of the Administrative Code, or, if located outside of Ohio, they may submit ink fingerprint impressions in a manner approved by the board.

(11) If there is a change in any of the following persons listed in paragraph (B)(9) of this rule, the new persons shall submit to a criminal records check within thirty days of the change.

(12) Any additional information required on the application as determined by the board.

(13) Any follow-up information as deemed necessary upon receipt of the application materials.

(9) Pursuant to division (A)(1) of section 4729.53 of the Revised Code, a new wholesale distributor of dangerous drug license with a third party logistics provider classification will not be issued until the owner(s), the officers (if incorporated) or agency directors (if a government agency) of the operation submit fingerprints to the Ohio bureau of criminal identification and investigation (BCI&I) for a criminal records check. If there is a change in officers, owners or agency directors, all new officers, owners or agency directors shall submit to a criminal records check. The criminal records check
shall consist of both a BCI&I criminal records check and a federal bureau of investigations records check (FBI). The results of the criminal records check must be sent directly to the Ohio state board of pharmacy from BCI&I. To be considered valid, the criminal records check must have been performed within the past twelve months. After the board receives the results of all of the required criminal records checks the license process will proceed. The owner(s) or officers may submit electronic fingerprint impressions pursuant to rule 4729-5-12 of the Administrative Code, or, if located outside of Ohio, they may submit ink fingerprint impressions as instructed on a form provided by the board.

(10) Any additional information as the state board of pharmacy may require.

(C) Prior to the end of the licensing period, a renewal application requesting such information as the state board of pharmacy may require will be sent to the attention of the responsible person. Such a renewal application shall be completed and returned with the applicable fee on or before the established deadline. As part of the renewal application, a person meeting the definition of a third party logistics provider that was licensed by the board as a wholesale distributor of dangerous drugs prior to the effective date of this rule shall demonstrate compliance with the requirements in paragraph (B)(8) of this rule. Failure to do so may result in a refusal by the board to renew the license.

(D) All facilities where dangerous drugs are stored, warehoused, handled, held, offered, marketed, or displayed shall:

(1) Be of suitable size and construction to facilitate cleaning, maintenance, and proper operations;

(2) Have storage areas designed to provide adequate lighting, ventilation, temperature, sanitation, humidity, space, equipment, and security conditions;

(3) Have a quarantine area for storage of dangerous drugs that are outdated, damaged, deteriorated, misbranded, or adulterated, or that are in immediate or sealed secondary containers that have been opened. Such drugs shall be stored no longer than two years pursuant to rule 4729-9-17 of the Administrative Code;

(4) Be maintained in a clean and orderly condition;

(5) Be free from infestation by insects, rodents, birds, or vermin of any kind.

(E) All facilities used for wholesale drug distribution shall be secure from unauthorized
entry.

(1) Access from outside the premises shall be kept to a minimum and be well controlled.

(2) The outside perimeter of the premises shall be well lighted.

(3) Entry into areas where dangerous drugs are held shall be limited to authorized personnel.

(4) All facilities where dangerous drugs are held shall be equipped with a state board of pharmacy approved alarm system to detect unauthorized entry after hours.

(5) All facilities shall be equipped with a security system that will provide suitable protection against theft and diversion. When appropriate, the security system shall provide protection against theft or diversion that is facilitated or hidden by tampering with computers or electronic records.

(F) All dangerous drugs shall be stored at appropriate temperatures and under appropriate conditions in accordance with requirements, if any, in the labeling of such drugs, or with requirements in the current edition of an official compendium, such as the United States pharmacopoeia/national formulary (USP/NF).

(1) If no storage requirements are established for a prescription drug, the drug may be held at "controlled" room temperature, as defined in an official compendium, to help ensure that its identity, strength, quality, and purity are not adversely affected.

(2) Appropriate manual, electromechanical, or electronic temperature and humidity recording equipment, devices, and/or logs shall be utilized to document proper storage of dangerous drugs.

(3) The recordkeeping requirements in paragraph (H) of this rule shall be followed for all stored drugs.

(G) All shipments of dangerous drugs shall be examined in accordance with the following:

(1) Upon receipt, each outside shipping container shall be visually examined for identity and to prevent the acceptance of contaminated dangerous drugs or
dangerous drugs that are otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents;

(2) Each outgoing shipment shall be visually examined for identity and to prevent the shipping of contaminated dangerous drugs or dangerous drugs that are otherwise unfit for distribution. This examination shall be adequate to reveal container damage that would suggest possible contamination or other damage to the contents;

(3) The recordkeeping requirements in paragraph (HI) of this rule shall be followed for all incoming and outgoing dangerous drugs.

(H) All returned, damaged, and outdated, dangerous drugs shall be handled in the following manner:

(1) Dangerous drugs that are outdated, damaged, deteriorated, misbranded, or adulterated shall be quarantined and physically separated from other dangerous drugs until they are destroyed or returned to their supplier.

(2) Any dangerous drugs whose immediate or sealed outer or sealed secondary containers have been opened or used shall be identified as such, and shall be quarantined and physically separated from other dangerous drugs until they are either destroyed or returned to the supplier.

(3) If the conditions under which a dangerous drug has been returned cast doubt on the drug's safety, identify, strength, quality, or purity, then the drug shall be destroyed, or returned to the supplier, unless examination, testing, or other investigation proves that the drug meets appropriate standards of safety, identity, strength, quality, and purity. In determining whether the conditions under which a drug has been returned cast doubt on the drug's safety, identity, strength, quality, or purity, the wholesale drug distributor shall consider, among other things, the conditions under which the drug has been held, stored, or shipped before or during its return and the condition of the drug and its container, carton, or labeling, as a result of storage or shipping.

(4) The recordkeeping requirements in paragraph (HI) of this rule shall be followed for all outdated, damaged, deteriorated, misbranded, or adulterated dangerous drugs.

(I) Wholesale drug distributors with a third party logistics provider classification shall establish and maintain inventories and records of all transactions regarding the
receipt and distribution or other disposition of dangerous drugs.

(1) These records shall include but not be limited to the following information:

(a) The source of the drugs, including the name and principle address of the seller or transferor, and the address of the location from which the drugs were shipped.

(b) The identity and quantity of the drugs received and distributed or disposed or returned.

(c) The dates of receipt and distribution of the drugs.

(d) A system of records and procedures shall be maintained which prevent the sale or other distribution of dangerous drugs to any person not authorized by division (B) of section 4729.51 of the Revised Code.

(e) A system shall be designed and operated to disclose orders for controlled substances and other dangerous drugs subject to abuse. Reports generated by the system shall be furnished to the state board of pharmacy within three working days of receipt of a request from the board. The reports shall include the name and address of the purchaser, date of purchases, product trade name, national drug code (NDC) number, size of package, and quantity purchased.

(2) Inventories and records shall be made available for inspection and photocopying by properly identified and authorized state board of pharmacy designated agents and federal, state, or local law enforcement agency officials for a period of three years following disposition of the drugs.

(3) Records described in this rule that are kept at the inspection site or that can be immediately retrieved by computer or other electronic means shall be readily available for authorized inspection during the retention period.

(a) Records kept at a central location apart from the inspection site and not electronically retrievable shall be made available for inspection within two working days of a request by properly identified and authorized state board of pharmacy designated agents and federal, state, or local law enforcement agency officials.

(b) Third party logistics provider intending to maintain records, described in
this rule, at a location other than the place licensed by the state board of pharmacy, must obtain approval from the board.

(J) Third party logistics providers shall inform the state board of pharmacy of suspicious orders for controlled substances and other dangerous drugs subject to abuse, immediately upon discovery. Suspicious orders are those which, in relation to the wholesaler’s records as a whole, are of unusual size, unusual frequency, or deviate substantially from established buying patterns.

(K) Third party logistics providers shall establish, maintain, and adhere to written policies and procedures which shall be followed for the receipt, security, storage, inventory, and distribution of dangerous drugs, including policies and procedures for identifying, recording, and reporting losses or thefts, and for correcting all errors and inaccuracies in inventories. Wholesale drug distributors shall include in their written policies and procedures the following:

(1) A procedure whereby the oldest approved stock of a dangerous drug product is distributed first. The procedure may permit deviation from this requirement, if such deviation is temporary and appropriate.

(2) A procedure to be followed for handling recalls and withdrawals of dangerous drugs. Such procedure shall be adequate to deal with recalls and withdrawals due to:

   (a) Any action initiated at the request of the food and drug administration or other federal, state, or local law enforcement or other government agency, including the state board of pharmacy;

   (b) Any voluntary action by the manufacturer to remove defective or potentially defective drugs from the market;

   (c) Any action undertaken to promote public health and safety by replacing of existing merchandise with an improved product or new package design.

(3) A procedure to ensure that third party logistics providers prepare for, protect against, and handle any crisis that affects security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency.

(4) A procedure to ensure that any outdated dangerous drugs shall be segregated from other drugs and either returned to the manufacturer or destroyed. This procedure shall provide for written documentation of the disposition of
outdated dangerous drugs. This documentation shall be maintained for three years after disposition of the outdated drugs.

(L) Third party logistics providers shall establish and maintain accurate and current lists of officers, directors, managers, and other persons in charge of wholesale drug distribution, storage, and handling, including a description of their duties and a summary of their qualifications.

(M) Personnel employed by the third party logistics providers shall be required to have appropriate education and/or experience to assume responsibility for positions related to compliance with the licensing regulations.

(N) Third party logistics providers shall operate in compliance with applicable federal, state, and local laws and regulations.

(1) Third party logistics providers shall permit properly identified and authorized state board of pharmacy designated agents; and federal, state, and local law enforcement officials to enter and inspect their premises and delivery vehicles, and to audit their records and written operating procedures at reasonable times and in a reasonable manner, to the extent authorized by law.

(2) A third party logistics provider making a wholesale sale of a controlled substance shall be required to possess a license as a wholesale distributor of dangerous drugs and a license as a wholesaler or manufacturer of controlled substances, except that a licensed terminal distributor of dangerous drugs may make an occasional sale of a controlled substance pursuant to rule 4729-9-10 of the Administrative Code.

(O) Third party logistics providers shall be subject to the provisions of any applicable federal, state, or local laws or regulations that relate to dangerous drug salvaging or reprocessing.

(P) The state board of pharmacy shall be notified within thirty days of any new facilities, work or storage areas to be constructed or utilized for dangerous drugs or of any changes in operation of the registrant third party logistics provider being used or implemented.

(Q) The wholesale distributor with a third party logistics providers provider classification shall comply with Title II of the Drug Quality and Security Act (9/3/2015).